5 Tips about Clinical effectiveness of ABBV-744 in AML patients You Can Use Today
In Segment C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the contributors are not able to tolerate the study drugs.For all circulation cytometry experiments, ten,000 cells for each replicate were analyzed, and 3 rep